RTSN stock news today

Oppenheimer starts Retension Pharmaceuticals coverage with Outperform rating and $50 price target

Oppenheimer began covering Retension Pharmaceuticals and gave the stock an Outperform rating. The firm set a price target of $50 per share.

Guggenheim starts Retension Pharmaceuticals coverage with Buy rating and $55 price target

Guggenheim began covering Retension Pharmaceuticals and rated the stock Buy. The firm set a price target of $55 per share.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

What is the latest news on RTSN?

Nov 3, 2026: Oppenheimer starts Retension Pharmaceuticals coverage with Outperform rating and $50 price target (Benzinga) · Nov 2, 2026: Guggenheim starts Retension Pharmaceuticals coverage with Buy rating and $55 price target (Benzinga) · Oct 22, 2026: Retension Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K) (SEC)

What has RTSN filed with the SEC recently?

Oct 22, 2026: Retension Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K) · Oct 22, 2026: Retension Pharmaceuticals, Inc. filed an insider trading report (Form 4)